Evolution of genome and immunogenome in esophageal squamous cell carcinomas driven by neoadjuvant chemoradiotherapy

Abstract

AbstractNeoadjuvant chemoradiotherapy (NCRT) followed by surgery is a standard treatment for locally advanced esophageal squamous cell carcinomas (ESCCs). However, the evolution of genome and immunogenome in ESCCs driven by NCRT remains incompletely elucidated. We performed whole‐exome sequencing of 51 ESCC tumors collected before and after NCRT, 36 of which were subjected to transcriptome sequencing. Clonal analysis identified clonal extinction in 13 ESCC patients wherein all pre‐NCRT clones disappeared after NCRT, and clonal persistence in 9 patients wherein clones endured following NCRT. The clone‐persistent patients showed higher pre‐NCRT genomic intratumoral heterogeneity and worse prognosis than the clone‐extinct ones. In contrast to the clone‐extinct patients, the clone‐persistent patients demonstrated a high proportion of subclonal neoantigens within pre‐treatment specimens. Transcriptome analysis revealed increased immune infiltrations and up‐regulated immune‐related pathways after NCRT, especially in the clone‐extinct patients. The number of T cell receptor–neoantigen interactions was higher in the clone‐extinct patients than in the clone‐persistent ones. The decrease in T cell repertoire evenness positively correlated to the decreased number of clonal neoantigens after NCRT, especially in the clone‐extinct patients. In conclusion, we identified two prognosis‐related clonal dynamic modes driven by NCRT in ESCCs. This study extended our knowledge of the ESCC genome and immunogenome evolutions driven by NCRT.